Travere Therapeutics Inc Stock Price, News & Analysis

Travere Therapeutics (NASDAQ: TVTX) said company management will participate in multiple investor conferences in November–December 2025, including Guggenheim Healthcare (Nov 11, 2025 at 9:00 a.m. ET), Stifel Healthcare (Nov 12, 2025), TD Cowen Immunology & Inflammation (Nov 13, 2025 at 4:00 p.m. ET), Jefferies Global Healthcare (Nov 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET), Evercore Healthcare (Dec 2, 2025 at 10:50 a.m. ET) and Piper Sandler Healthcare (Dec 3, 2025).

Live webcasts of presentations will be available on the company investor page at ir.travere.com/events-and-presentations, with replays accessible for up to 30 days after each event.

Travere Therapeutics (NASDAQ: TVTX) reported 3Q 2025 total revenue of $164.9 million, which included a $40.0 million market access milestone and license revenue. The company reported a $25.7 million net income for 3Q 2025 (or $0.29 per basic share) versus a net loss in the year-ago quarter and held $254.5 million in cash, cash equivalents and marketable securities as of Sept 30, 2025. FILSPARI commercial momentum continued: the release cites 155% year-over-year U.S. growth and program updates ahead of a PDUFA target action date of Jan 13, 2026 for FSGS. The company also repaid roughly $68.9 million of 2025 convertible notes and reported progress on pegtibatinase development and global partnerships.

Travere Therapeutics (NASDAQ: TVTX) will report third quarter 2025 financial results on Thursday, October 30, 2025 after market close.

The company will host a conference call and webcast to discuss results and provide a business update at 4:30 p.m. ET. Webcast and dial-in details are available on Travere's Investor Events page, and an archived recording will be available for 30 days after the live event.

Travere Therapeutics (Nasdaq: TVTX) will present 11 abstracts at ASN Kidney Week 2025 in Houston, Nov 6–9, 2025.

Key highlights include a late-breaking DUPLEX analysis showing more FILSPARI (sparsentan)-treated patients reached proteinuria <0.7 g/g versus maximum labeled irbesartan, and that reaching this threshold correlated with reduced kidney failure risk regardless of treatment arm. Additional DUPLEX data show rapid, sustained proteinuria reductions in children and in patients with COL4A3-5 variants. SPARTAN presentations report anti-inflammatory and anti-fibrotic biomarker effects in RASI-naïve IgAN patients and favorable cardiovascular safety signals, plus real-world evidence and PROTECT analyses of consistent, superior proteinuria reduction with FILSPARI.

Travere Therapeutics (NASDAQ: TVTX) announced on October 10, 2025 that its Compensation Committee approved inducement equity grants covering an aggregate of 228,600 shares to 43 new employees.

The awards comprise inducement stock options for 50,000 shares and inducement restricted stock units (RSUs) for 178,600 shares, granted outside the 2018 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $25.16 (closing price on the grant date), are non-qualified, carry a 10-year term and vest over four years (25% after one year, then monthly over 36 months). The RSUs vest over four years with 25% vesting on each anniversary. All awards vest subject to continued service.

CSL Vifor (OTC:CSLLY) and Travere Therapeutics announced recognition of updated KDIGO clinical practice guidelines for IgA Nephropathy (IgAN) treatment. The 2025 guidelines highlight their drug FILSPARI® (sparsentan) as a potential first-line treatment approach, being the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA) with proven efficacy compared to optimized RASi in clinical trials.

The updated guidelines establish key treatment goals including proteinuria remission and slowing eGFR decline. FILSPARI, which is approved in the U.S. and Europe, has been launched in multiple European countries including Germany, Austria, Switzerland, Luxembourg, and the UK. The guidelines were presented at the International Symposium of IgA Nephropathy in September 2025.

Travere Therapeutics (NASDAQ: TVTX) announced the granting of inducement equity awards to 20 new employees. The Compensation Committee approved restricted stock units (RSUs) covering 69,300 shares of common stock on September 10, 2025.

The RSUs were granted outside of the company's 2018 Equity Incentive Plan but are subject to its terms. These grants, made under Nasdaq Listing Rule 5635(c)(4), will vest over four years with 25% vesting annually, contingent on continued employment.

Travere Therapeutics (Nasdaq: TVTX) announced that the FDA will no longer require an advisory committee meeting for the supplemental New Drug Application (sNDA) of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The PDUFA target action date remains January 13, 2026.

The sNDA is supported by the Phase 3 DUPLEX and Phase 2 DUET studies, which demonstrated FILSPARI's superior efficacy in reducing proteinuria compared to irbesartan. Notably, patients achieving proteinuria remission showed a 67% to 77% lower risk of kidney failure. If approved, FILSPARI would become the first medication specifically indicated for FSGS treatment.

Travere Therapeutics (Nasdaq: TVTX) presented long-term safety and efficacy data for pegtibatinase in treating classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism in Kyoto, Japan.

The Phase 1/2 COMPOSE open-label extension study showed that patients receiving the target dose of 2.5 mg/kg twice weekly maintained significant metabolite reductions over 50 weeks, including a 53.5% reduction in total homocysteine and a 67.1% reduction in methionine. Notably, homocysteine levels remained below the clinical guideline threshold of 100 µM, and the treatment was generally well-tolerated with no new safety concerns.

The company plans to restart enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for classical HCU treatment in 2026.